Immunology/Inflammation (Host-Directed)

The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.

Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.

Volatylix, a Cambridge, MA based startup, is dedicated to early diagnosis enabling timely and appropriate treatment benefiting the patient, physician, provider and payor. Our patent pending platform – DECIPHER – and unique detection sensor technology – OFIS - combine to identify various disease states and conditions via proprietary breath biomarkers, volatile organic compounds (VOC’s). DECIPHER is disease agnostic and will speed diagnosis, while improving accuracy over currently available diagnostic methods. The tests use a noninvasive 4-minute breath sample with analysis taking ~15 minutes on our portable, battery powered platform. Initial products include fungal pneumonias, lung cancer (staging, monitoring, differential diagnosis and screening) and C. difficile.

FiteBac Technologies/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.

Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.

The National Foundation for Integrative Medicine (NFIM) is dedicated to transforming healthcare through innovative solutions and technologies. With a mission to shorten the technology transition cycle and improve health outcomes, NFIM focuses on patient care innovation and supports various populations, including veterans and clinicians, in accessing safer and more effective healthcare options.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.

The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

The Institute for Integrative & Innovative Research (I³R) at the University of Arkansas is dedicated to pioneering solutions to wicked problems and societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I³R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.

UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.

HDT Bio is a clinical-stage biopharmaceutical company based in Seattle, developing novel technologies and products designed to harness and enhance the immune system for the treatment and prevention of cancer and infectious diseases. HDT Bio utilizes advanced immunotherapeutic platforms, including a proprietary nanoparticle delivery system, to provide safe, potent, and durable solutions that enable rapid clinical translation and personalized cancer therapies. The company's multidisciplinary team and international partnerships facilitate robust clinical development, innovative product design, and global distribution with the goal of improving patient outcomes worldwide.

The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.

Harmac is a global contract design and manufacturing organization specializing in single-use medical devices. With over four decades of experience, Harmac provides comprehensive services including product design and development, advanced manufacturing, automation, value engineering, quality assurance, and packaging and sterilization. The company is known for its operational excellence, regulatory compliance, and commitment to sustainability and community engagement. Harmac operates facilities across the United States, Ireland, and Mexico, supporting customers worldwide and across a range of clinical applications. ISO 13485 Certified and FDA Registered.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Cooper University Health Care is a regional academic health system recognized for comprehensive clinical services, advanced multidisciplinary care, specialized surgery, and robust research in South Jersey. It provides integrated healthcare across general and specialty domains, including cancer, neurosciences, cardiology, trauma, genetics, addiction medicine, and complex surgical procedures, supported by leading technologies and a network of modern facilities.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment, utilizing Systems Biology and AI/ML. Evimero applies molecular principles to infectious disease and microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes and in people with infectious disorders. Evimero has an infectious disease product pipeline including both prophylactic and diagnostic assets against common causes of Travelers' Diarrhea, including a unique approach to preventing infection with human Norovirus, enterotoxigenic E. coli (ETEC) and others. Evimero's pipeline of drugs targeting human and animal microbiomes includes early-stage assets aimed at generalized microbiome-driven inflammation and gut leak, and specific disease-targeted disorders including Parkinson Disease and Inflammatory Bowel Diseases. Evimero's platform also makes possible a suite of point-of-care diagnostics that can be used for patient cohorting (infectious diseases), risk stratification, and ultimately informing therapeutic decision-making. The nature of Evimero's platform assures a steady stream of novel assets targeting both infectious diseases and chronic disorders with roots in microbiome dysfunction.

Innospera Pharma is a privately held biotechnology company based in Montreal, focused on developing small-molecule modulators targeting G-protein coupled receptors (GPCRs), particularly GPR84 and GPR40, for the treatment of chronic, fibrotic, inflammatory, and metabolic diseases. Its pipeline includes next-generation lipid-mimetic compounds designed to address unmet medical needs, with lead candidates intended for conditions such as idiopathic pulmonary fibrosis and various cardiometabolic disorders. The company leverages extensive scientific expertise and preclinical data and is supported by investors such as Investissement Québec, Seido Capital, and Anges Québec.

IAVI is a nonprofit scientific research organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. Their mission is to translate scientific discoveries into affordable, globally accessible public health solutions, aiming for a world where all people have equitable access to innovative vaccines and therapeutics.

IntegerBio is at the forefront of Immunovirology, committed to combating serious viral diseases by pioneering the intersection of immunology and virology. The company focuses on developing broad multi-viral therapeutics using cutting-edge biology and data-focused approaches. Their mission is to harness the power of science to design therapeutics with durable responses across multiple viruses, aiming for a future without the fear of viral disease.

Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.

The Nanovaccine Institute, established at Iowa State University in 2017, is a national transdisciplinary research consortium focused on advancing nano-based technologies to treat and prevent diseases. The institute aims to revolutionize public health outcomes through the design and promotion of nano-based vaccines and therapeutics.

The UVM An-Cockrell Lab Center for Biomedical Digital Twins is a multidisciplinary research group leveraging advanced computational methods, including machine learning, agent-based modeling, and high-performance computing, to study complex biomedical and physiological phenomena. Their mission is to bridge the gap between basic science and clinical interventions by developing digital twins and computational models that inform precision medicine, therapeutic discovery, and translational research. The lab's work spans detailed organ and disease modeling, AI-driven clinical applications, and collaborative projects such as DARPA-funded initiatives, aiming to revolutionize healthcare through technology and simulation.

Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on developing and commercializing a novel class of specifically targeted polyclonal antibodies. The company aims to address significant unmet medical needs, particularly in treating gastrointestinal disorders caused by pathogenic bacteria. Immuron has established partnerships with leading research institutions and companies to enhance its product development and manufacturing capabilities. The company is currently advancing its drug candidates through clinical development, targeting conditions such as Campylobacteriosis, recurrent Clostridiodes difficile infections, and travelers’ diarrhea. Immuron is also engaged in various scientific studies and collaborations to further its research and product efficacy. The company has a proprietary technology platform and is committed to transforming treatment paradigms for gastrointestinal health.

Florida Research & Innovation Center (FRIC) is a biomedical research organization specializing in infectious and inflammatory diseases, immunology, vaccine development, cancer biology, and organ transplantation immunology. The center emphasizes both basic and translational research, investigating mechanisms of disease, host-pathogen and host-tumor interactions, and sex-specific immune mechanisms. FRIC supports research with advanced core facilities in flow cytometry, imaging, and bioinformatics, and provides hands-on education and workforce development in biomedical research.

Keylicon Biosciences is developing the next generation of self-amplifying RNA (saRNA) to deliver low-dose, durable vaccines and therapeutics. Our platform produces multivalent vaccines that generate long-lasting immunity from low doses, and can express therapeutic proteins directly within diseased tissues, such as tumors, with high specificity following systemic administration.

Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world, dedicated to providing high-quality, patient-centered care. With a history of innovation spanning nearly 150 years, Mayo Clinic is committed to transforming healthcare through research, education, and compassionate care, ensuring that the best possible treatment is available to everyone.

Taurus Vaccines LLC, founded in 2024 and based in Austin, Texas, is a biotechnology company that designs and develops innovative vaccines for livestock including cattle, horses, goats, and sheep. The company leverages proprietary viral vector technology to induce robust cytotoxic T lymphocyte and humoral immune responses against infectious diseases affecting production animals. While focused on early-stage research and pre-licensing vaccine development, Taurus Vaccines also supports field trials and regulatory registration, facilitating the transition of pipeline inventions to commercial manufacturers through licensing. The company's mission is to advance the availability of effective, science-driven vaccines for global animal health needs.

Temple University is Philadelphia’s only public university and a global center of academic excellence. It is classified as an R1 institution, indicating very high research activity, and offers over 600 academic programs across 17 diverse schools and colleges. The university is committed to providing accessible education that fosters positive change and prepares students to become leaders in their fields. Additionally, Temple emphasizes a vibrant campus life enriched by arts, culture, and a commitment to diversity and inclusivity. The university also promotes a tobacco-free environment to enhance the health and well-being of its community. Temple's athletics program further enhances student life, with 19 varsity teams competing at the NCAA Division I level, fostering school spirit and community engagement.

The Office of Sponsored Projects Administration (OSPA) at the University of Kentucky is dedicated to transforming tomorrow by streamlining grants and contracts. OSPA provides essential services to faculty and staff, including assistance with proposal preparation, award negotiation, and compliance with sponsor policies.

Southwest Research Institute (SwRI) is a nonprofit research and development organization that provides independent, premier services to government and industry clients. Founded in 1947, SwRI is committed to advancing science and technology to benefit humanity, focusing on innovative solutions that improve human health and safety. With a diverse range of technical divisions, SwRI addresses complex challenges in various fields including mechanical engineering, materials, aerospace, automotive, biomedical, and more.

JURA Bio is pioneering AI-native drug discovery by bridging the gap between computational design and physical reality in biological AI. Their mission is to revolutionize the discovery and development of safe and effective drugs, making even the hardest therapeutic targets tractable. By leveraging manufacturing-aware generative models, JURA Bio not only designs new therapeutics but also builds, tests, and learns from them at unprecedented scale. Their approach integrates machine learning, synthetic biology, and high-throughput experimentation to create a new paradigm in drug discovery, where AI learns from tens of billions of real protein interactions and every candidate is inherently human-safe.

Swaza Inc. is a biotechnology company focused on developing revolutionary oxygen nanotherapeutics. Their mission is to provide innovative solutions for respiratory distress through non-invasive nanofluid breathing aids and advanced regenerative biomaterials, leveraging their proprietary nanotechnology platform.

The University of Texas at Dallas (UT Dallas) is a top public research university located in Richardson, Texas, known for its innovative programs, renowned faculty, and a commitment to academic excellence. With over 31,000 students across seven schools, UT Dallas offers a diverse range of undergraduate and graduate programs designed to prepare students for leadership roles in various fields including science, engineering, business, and the arts. The university emphasizes research, community engagement, and student success, making it a vibrant hub for learning and innovation. Additionally, UT Dallas is recognized for its strong return on investment, high graduation rates, and successful career placement for graduates, with many students continuing their education at prestigious graduate schools.

The University of Arizona Applied Research Corporation (UA-ARC) is a non-profit organization affiliated with the University of Arizona, dedicated to leveraging the university's strengths in research and education to address national security challenges. UA-ARC aims to deliver innovative solutions and foster collaborations between academia, industry, and government.

The University of Utah (UU) is a leading research institution recognized for its research activity and commitment to innovation and discovery. As an R1 Institution, it is dedicated to advancing knowledge and solving critical problems that challenge our national security interests and impact the global community. We foster interdisciplinary collaboration and provide resources to drive transformative research focused on enhancing medical care superiority for the U.S. Department of Defense (DoD) through advanced medical and engineering research sponsored by our Applied Medical & Engineering Laboratory (AM&E Lab). As a leading public university, UU also provides healthcare services to seven states in the Intermountain West, with the largest catchment of remote and austere frontier territory for any academic center. Leveraging its geographic advantage, technological and commercialization strengths, expertise in medical services, and leading-edge, core engineering competencies, UU is uniquely positioned to address the nation's critical national security interests.

The Institute for Biohealth Innovation (IBI) at George Mason University unites over 300 faculty and thousands of students across 34 departments to advance human health and well-being through innovative research. The IBI focuses on major health challenges, including infectious diseases, cancer, brain and behavior, and cardiovascular health, collaborating with national and international partners to implement solutions that enhance health outcomes.

The University of Minnesota's Research and Innovation Office (RIO) serves as a central resource for conducting, managing, and sponsoring research. It aims to facilitate collaborative research that addresses complex problems and promotes innovations that improve lives. RIO oversees research compliance and administration, fostering a culture of integrity and ethical practices in research. Additionally, RIO is committed to enhancing research capacity through various funding opportunities and strategic initiatives, including the management of specialized facilities for biocontainment research.

The University of Notre Dame, founded in 1842, is a prestigious Catholic research university located in South Bend, Indiana. It is dedicated to providing a holistic education that integrates faith, reason, and service to others. The university aims to be a leading global Catholic research institution, fostering a community of scholars committed to inquiry, justice, and the common good.

New York University (NYU) is a global university that connects talented and ambitious individuals in some of the world's greatest cities. Its mission is to be a top-quality institution, providing a diverse range of academic programs and opportunities for students to engage with the world's challenges. NYU is committed to fostering innovation and entrepreneurship, and it emphasizes diversity, equity, and inclusion in its educational mission. Founded in 1831, NYU has evolved to become a leader in higher education, with a commitment to accessibility and a diverse student body. NYU offers a wide array of academic programs, including accelerated studies and online education, catering to the needs of a global student population.

MiNK Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, pulmonary, and immune-mediated diseases. The company advances a platform of off-the-shelf, native and engineered iNKT cell programs capable of targeting tumors and modulating immune responses, with demonstrated clinical evidence in oncology, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis. Its manufacturing platform enables large-scale GMP-compliant production and clinical delivery of iNKT cell therapies without lymphodepletion or HLA matching. MiNK collaborates with leading academic and industry partners to advance novel cell-based immunotherapies.

The Wyss Institute for Biologically Inspired Engineering uses biological design principles to develop new engineering innovations that will transform medicine and create a more sustainable world. At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

Remedor Biomed is a clinical research stage biopharmaceutical company focused on revolutionizing complex wound treatment through patented technology. The company aims to provide innovative solutions for diabetic foot ulcers and complex skin wound conditions, significantly impacting patients' lives and healthcare systems.

Vasomune Therapeutics is a private clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases associated with vascular dysfunction. Their lead drug candidate, Pegevongitide (AV-001), enhances the body's ability to reverse vascular endothelial instability and vascular leak, particularly in conditions such as Acute Respiratory Distress Syndrome (ARDS), hemorrhage, and following toxin exposure.

Northwestern University is a prestigious institution dedicated to fostering a diverse and inclusive environment, promoting academic excellence, and engaging in impactful research. With campuses in Evanston, Chicago, and Doha, Qatar, Northwestern emphasizes global engagement and community involvement, preparing students to tackle complex challenges through interdisciplinary collaboration and innovative thinking.

Digital Ether Computing (DEC) is a Florida–based company that develops adaptive AI for drug discovery, functional genomics, and defense health applications. DEC's proprietary platforms (Liquid Adaptive AI, LC-JT-VAE generative molecular design, and the Dynamicasome genomic atlas) identify hidden (cryptic) binding pockets and design novel therapeutics against targets once considered undruggable, from computational prediction through partner-led synthesis and validation. DEC's technology is described in peer-reviewed publications and protected by four provisional patents, and the company currently performs under a Florida Department of Health Cancer Innovation Fund contract. DEC is SAM.gov registered (CAGE 131L8, UEI R8TDWGCLKUH1) and U.S./Canada Joint Certification Program (JCP) certified for access to DoD export-controlled technical data, and welcomes prime and subcontractor teaming on MTEC and federally funded research programs.

The University of Alaska Fairbanks (UAF) is a Land, Sea, and Space Grant university and an international center for research, education, and the arts, emphasizing the circumpolar North and its diverse peoples. UAF integrates teaching, research, and public service as it educates students for active citizenship and prepares them for lifelong learning and careers.

ClearCure Biosciences is a clinical-stage biopharmaceutical company focused on developing non-toxic, first-in-class and best-in-class therapies for cancer, infectious diseases, sepsis, neurological diseases, and cardiovascular conditions. The company emphasizes drugging challenging targets, leveraging proprietary small molecules, nanotechnology, new oncology cell therapies, new transdermal drug delivery technology, AI and omics-driven approaches, and digital health solutions to address serious unmet medical needs. The company is currently seeking collaborators and partnerships.

The University of Arkansas for Medical Sciences Office of Research and Sponsored Programs (ORSP) is dedicated to supporting UAMS faculty in acquiring, performing, and administering projects funded by external sources. The ORSP ensures compliance with policies, negotiates award terms, liaises between investigators and sponsors, and manages subcontracts.

Founded by Thomas Jefferson in 1819, the University of Virginia is a prestigious public university that emphasizes the advancement of human knowledge, education of leaders, and cultivation of an informed citizenry. It is recognized for its commitment to academic excellence, vibrant student life, and a strong alumni network, making it one of the top public universities in the United States.

The University of Missouri is dedicated to advancing research, innovation, and impact through a comprehensive support system for faculty, students, and staff. It aims to foster collaboration, enhance economic development, and promote entrepreneurship, while ensuring compliance with research regulations and ethical standards. The university also emphasizes the importance of interdisciplinary partnerships and provides resources to support veteran entrepreneurs through programs like the Entrepreneurship Bootcamp for Veterans.

The University of Massachusetts Lowell (UML) is dedicated to providing a comprehensive educational experience that prepares students for success in their careers and lives. With over 200 degree programs and a commitment to research and community engagement, UML fosters a vibrant learning environment for its diverse student body.

ICaPath, Inc. is a biotechnology company developing immunotherapy solutions for cancer and serious diseases, with a focus on patent-protected, PLGA-based nanoparticle drug delivery systems. The company's platform enables controlled, sustained-release delivery of cytokines such as interleukin-12, improving immune stimulation while reducing toxicity. This approach is complemented by immune profiling diagnostics for precision medicine, and the company includes expertise spanning biologics manufacturing, translational research, and regulatory advancement for new therapies.

Novilla develops AI-designed localized therapeutics to treat pain and inflammation by targeting specific tissues and minimizing systemic side effects. The company's mission is to transform pain care and reduce opioid-related risks by enabling effective, site-specific treatments. Novilla integrates expertise in drug delivery, chemical thermodynamics, and machine learning to address indications such as gout, diabetic circulatory insufficiency, joint inflammation, muscle spasms, and postoperative pain.

The University of Nebraska Medical Center (UNMC) is dedicated to transforming lives through premier educational programs, innovative research, and extraordinary patient care. Founded in 1869, UNMC is a leader in health sciences education and research, serving as a vital resource for Nebraska and beyond.

MassBiologics, part of UMass Chan Medical School, is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States. With over 100 years of experience, it is dedicated to improving public health through the research, development, and production of biologic products, including vaccines and monoclonal antibodies.

The University of Florida is a leading public university that fosters innovation, education, and research. With a commitment to excellence, the university provides a diverse and inclusive environment for students, faculty, and staff, driving impactful discoveries and community engagement.

The UCI Office of Research is dedicated to supporting and enhancing the creative and scholarly activities of UCI faculty and researchers. It provides central administrative support for research programs, ensuring compliance with regulations and fostering an environment conducive to research and innovation.

Caleo Biotechnologies develops patient-derived human translational models for preclinical therapeutic development. Our proprietary Organ-Dish™ platform generates multicellular 3D tissue models directly from human biospecimens while preserving key epithelial, stromal/mesenchymal, and immune compartments and features of native tissue biology. The platform enables evaluation of therapeutic efficacy, tissue injury and repair, inflammation, immune response, fibrosis and remodeling, and translational biomarkers in a patient-relevant human system. Organ-Dish™ models are scalable and compatible with pharmacologic, biologic, and cell-based therapeutic testing and downstream molecular and histologic analyses. Our approach aligns with the FDA’s increasing emphasis on human-relevant New Approach Methodologies (NAMs) to strengthen preclinical evidence and reduce reliance on animal testing. CaleoBio is interested in partnerships with therapeutic developers, biotechnology companies, academic investigators, and government/DoD teams seeking human translational models to support preclinical R&D and therapeutic development. Current and expanding applications include gastrointestinal disease, traumatic and complex wounds, pulmonary fibrosis, liver disease, and oncology.

The GE HealthCare Technology & Innovation Center (HTIC) traces its roots to America's first industrial research facility, established by General Electric in 1900. Today, HTIC scientists tackle healthcare challenges through federal funding, academic collaboration, and private sector development. HTIC enhances GE HealthCare competitiveness through development of innovative technologies that enable creation of differentiated and disruptive products. HTIC engages in exploratory research in collaboration with clinicians and academia, guided by societal needs and governmental priorities to discover new markets. With operations in Niskayuna, NY, USA and Bangalore, India, HTIC translates federal research investments into clinical applications.

Senovia Biosciences is developing pharmaceutical therapies that aim to modulate metabolic state as a core variable in the treatment of diverse diseases. The company's mission is to restore health by controlling metabolic state rather than focusing exclusively on molecular targets, supported by published evidence across neurology, psychiatry, oncology, cardiology, immunology, and infectious disease. Senovia applies a unified platform approach—Metabolic State Medicine—to address bioenergetic dysfunction, serving as an upstream driver for multiple chronic conditions. Its programs serve several high unmet-need indications and are built on a platform of state actuators: oral medicines designed to achieve, titrate, and sustain specific metabolic states safely for chronic use, without dietary restriction.

Virginia Tech is a leading research institution dedicated to improving the quality of life and the human condition through education, research, and community engagement. With a commitment to its motto, 'Ut Prosim' (That I May Serve), Virginia Tech fosters a collaborative environment that integrates technology into all disciplines, preparing scholars to be leaders and problem-solvers.

CureLab Veterinary is a biotechnology company focused on the development of gene-based therapies targeting cancer and chronic inflammatory diseases in companion animals, such as dogs, cats, and horses. Utilizing advances in comparative medicine and translational immunology, the company applies a plasmid-based platform to stimulate anti-cancer immune responses, modulate tumor microenvironments, and mitigate chronic inflammation. Clinical research leverages academic partnerships and a robust intellectual property portfolio, pursuing efficient regulatory approval pathways in major markets, including the US and Europe. Recent studies suggest broader applications in pain management and cross-species translational potential.

LSU Health Sciences Center New Orleans is dedicated to educating future health professionals and scientists, advancing research, and providing exceptional healthcare. With six professional schools and numerous affiliated hospitals, LSUHSC-NO aims to improve health outcomes and address health equity challenges in Louisiana.

The University of Texas Permian Basin (UTPB) offers a modern, affordable education in the heart of West Texas, focusing on student success and community impact. With a commitment to providing a diverse range of undergraduate and graduate programs, UTPB aims to empower students to achieve their academic and career goals while contributing positively to the region. UTPB also emphasizes professional development through innovative programs like the Coursera Career Academy and the Impact Behavioral Health Scholarship, which covers tuition and fees for graduate students in specific programs.

Biomeme is dedicated to advancing global health through innovative molecular detection technologies. Their mission is to provide rapid, reliable diagnostics that empower healthcare providers and researchers to make informed decisions in real-time, ultimately improving patient outcomes and public health responses. Biomeme emphasizes the importance of One Health, recognizing the interconnectedness of human, animal, and environmental health. They are at the forefront of combating antibiotic resistance through multifaceted approaches, including Host Response research, testing, and robust advocacy initiatives. Additionally, Biomeme fosters a culture of innovation and creativity, empowering its team to develop novel solutions for global health challenges.

NaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.

Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.

Texas Biomedical Research Institute (Texas Biomed) is a leading nonprofit biomedical research organization with more than 80 years of experience supporting the development of medical countermeasures for emerging and high-consequence infectious diseases. Texas Biomed provides comprehensive in-vitro and in-vivo preclinical research services supporting the discovery, development, and evaluation of vaccines, therapeutics, diagnostics, and other medical countermeasures from early discovery through preclinical proof-of-concept, efficacy, and translational research. Studies can be conducted under GLP or GLP-like quality frameworks, as appropriate to program stage and sponsor requirements, with integrated quality assurance and study compliance support. The Institute operates state-of-the-art ABSL-2, ABSL-3, as well as the only privately operated BSL-4 research facilities, together with the Southwest National Primate Research Center, enabling studies in small animal and nonhuman primate models under high-containment conditions. Texas Biomed has extensive expertise in virus propagation and characterization, antiviral and neutralization assays, molecular diagnostics, immunology, pathology, bioinformatics, animal model development, natural history studies, efficacy testing, pharmacology, and biomarker evaluation across a broad range of viral pathogens, including filoviruses, henipaviruses, arenaviruses, alphaviruses, flaviviruses, coronaviruses, hantaviruses, and other emerging and biodefense-relevant viruses. Pathogen expertise includes, but is not limited to, Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), Marburg virus (MARV), Nipah virus (NiV), Lassa virus (LASV), Junín virus (JUNV), Machupo virus (MACV), Western equine encephalitis virus (WEEV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Dengue virus (DENV) and SARS-CoV-2. With decades of experience supporting Animal Rule programs and infectious disease research, Texas Biomed delivers integrated, high-quality preclinical solutions for government, industry, and academic partners developing medical countermeasures for BSL-2, BSL-3, and BSL-4 pathogens.

The University of Montana (UM) is a flagship public research university located in Missoula, Montana. Established in 1893, UM offers a wide range of undergraduate and graduate programs, emphasizing research, creativity, and community engagement. With a commitment to academic excellence and public service, UM aims to transform lives through education and research, fostering a diverse and inclusive environment for its students.

CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.

Egret Therapeutics is a biotechnology company developing a novel therapy that targets the immune-mediated component of secondary neuronal damage to improve recovery after TBI. Our therapy has potential applications across combat injury (TBI, SCI, MSK, and polytrauma) and civilian markets (heart attack, stroke), where immune-mediated secondary damage leads to devastating outcomes.

UC San Francisco is a leading university dedicated to advancing health worldwide through preeminent biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. With a commitment to public service, UCSF aims to innovate health care approaches for vulnerable populations and train the next generation of health professionals.

VitaKey is pioneering a new era in nutrition by applying precision delivery technology to enhance the nutrient density of foods and beverages. Developed at MIT, Langer Lab, and co-founded by Dr. Robert S. Langer, VitaKey's platforms aim to address global health challenges, including diet related diseases such as obesity, heart disease and diabetes. VitaKey technologies ensure the stability and controlled release of nutrients (macronutrients, micronutrients, probiotics, bioactives, etc.) to improve bioavailability and enhance the functionality of foods and beverages. VitaKey creates all natural food and beverage solutions to enhance human performance, boost satiety, and improve the health and wellness of all consumers.

SUNY Upstate Medical University is a leading academic medical center in Central New York, dedicated to providing exceptional patient care, advancing medical research, and educating future healthcare professionals. As the region's only Level I trauma center and a Magnet recognized institution, Upstate is committed to delivering cutting-edge, life-saving treatments and fostering a compassionate, patient-centered environment. The university also plays a significant role in the community through outreach programs and is recognized as one of America's best large employers by Forbes.

We are UK/US entity with a team based in Maryland and North Carolina comprising an expert team that has linked triggers to disease states including TBI and acute injuries associated with radiation, acute lung injury and infection.

Washington State University (WSU) is a public research university dedicated to improving lives by serving the public good. With a commitment to unlocking possibilities, WSU empowers students, faculty, and others to create a world where all people can thrive. The university offers a diverse range of academic programs across its six campuses and is recognized for its high research activity and community engagement.

BiosYnth s.r.l. is a biotechnology firm specializing in the research, development, and innovation of bacterial and viral vaccine platforms. With over 40 years of expertise, the company focuses on glycoconjugate, nanostructured vector, and synthetic peptide technologies to address invasive infectious diseases and antibiotic resistance. Operations comply with GLP and GMP standards and are supported by a robust patent portfolio and international collaborations.

UCLA is a leading public research university located in Los Angeles, California. It is renowned for its commitment to the creation, dissemination, preservation, and application of knowledge for the advancement of global society. With a rich history of academic and athletic excellence, UCLA offers a comprehensive environment that supports both academic and personal growth. The university is dedicated to fostering innovation and making a significant impact on the world through groundbreaking research and transformative practices.

VLP Therapeutics is a Maryland-based biotechnology company established in 2012, focused on developing preventative and therapeutic vaccines as well as targeted antibody agents for cancer, infectious diseases, autoimmune conditions, and neurological diseases. The company utilizes next-generation virus-like particle platforms, gene delivery systems, and structure-based antigen design to address unmet global medical needs. Its research pipeline includes vaccine candidates for malaria, dengue, COVID-19, and cancer immunotherapies. The organization is driven by a team with experience in vaccine R&D, clinical development, and collaborative partnerships with prominent academic and government institutions.

Riptide Bioscience develops engineered peptides derived from host defense peptides found widely in nature. Riptide has developed an antimicrobial peptide, RP557, with extraordinary potential to address battlefield and complex traumatic wounds, both at the point of injury and during continuing care. RP557, once clinically translated will have the following favorable characteristics: • Broad spectrum antimicrobial activity thereby allowing empiric treatment, • Active against multidrug resistant organisms, including MRSA and P. aeruginosa, • Rapid bactericidal effect, • Less prone to pathogen resistance development, • Able to prevent biofilm formation, • Effective against established biofilm, • High Therapeutic Index, • Suppresses inflammatory responses (improves quality of healing; cosmesis and function), and • Accelerates wound healing.

Rx Bandz is dedicated to developing innovative, next-generation auto-injectors and life-saving formulations that provide simple solutions for patients, first responders, and the military. Their mission is to enhance the delivery of injectable medications, ensuring accessibility and ease of use for anyone, anytime, anywhere.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Advanced Light Devices manufactures the patent pending Hemealumen Polychromatic Device Innovative Solutions for Treating Infectious and Neurodegenerative Diseases Company Overview Advanced Light Devices is a pioneering company established in the early 2000s, dedicated to developing advanced medical technologies for the treatment of a range of diseases. With a vision to revolutionize healthcare, the company focuses on innovative therapies that utilize light-based technology to address complex medical challenges. The Hemealumen Polychromatic Device At the core of Advanced Light Devices' portfolio is the Hemealumen Polychromatic Device, a state-of-the-art medical tool designed to combat both viral and bacterial diseases. In addition, this device is being used as a therapeutic option for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. Applications in Infectious Disease Treatment The Hemealumen Polychromatic Device has demonstrated effectiveness in treating a variety of infectious diseases, including: Malaria Dengue fever COVID-19 Zika virus Shingles By utilizing targeted polychromatic light, the device disrupts the replication and survival mechanisms of pathogens, offering a non-invasive and innovative approach to disease management. Blood Treatment During Transfusions The Hemealumen Polychromatic Device is also used to treat blood during transfusions, effectively eliminating bacteria and viruses. This process enhances the safety of blood transfusions, reducing the risk of transfusion-transmitted infections and improving patient outcomes. Impact on Neurodegenerative Diseases Beyond infectious diseases, the device shows promise in the management of neurodegenerative conditions such as ALS and Parkinson's disease. Its mechanism of action may help reduce the progression of these disorders, though further research is ongoing to fully understand its therapeutic potential. Conclusion Advanced Light Devices, through the Hemealumen Polychromatic Device, is at the forefront of medical innovation. Their commitment to developing effective treatments for both infectious and neurodegenerative diseases position them as a leader in the field of light-based medical technology.

The Vanderbilt School of Engineering is a globally recognized academic and research institution dedicated to producing leaders and innovators in engineering. With a commitment to solving grand challenges, the school offers a diverse range of undergraduate and graduate programs across multiple engineering disciplines, fostering a culture of collaboration and excellence.

Partner Therapeutics, Inc. (PTx) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer and other serious diseases. With a strong foundation in oncology, PTx also leads research in infectious diseases, immunology, and urgent clinical needs such as COVID-19 and sepsis. The company integrates research, manufacturing, development, and commercialization to rapidly bring therapies to patients worldwide, emphasizing collaboration with medical and scientific communities to improve patient outcomes and quality of life. PTx's mission-driven approach is supported by a leadership team with deep industry experience and a commitment to advancing late-stage therapeutics that address significant unmet medical needs. The company also maintains a robust compliance program in accordance with state and federal regulations.

A rescue nasal spray for traumatic brain injury! Under AFIRM-002, Advancing Therapeutic Reprogramming for Military Regenerative Medicine, Diadem Biotherapeutics is advancing DB503, an engineered extracellular vesicle (EV) therapeutic displaying TNF-stimulated gene-6 (TSG-6) protein, formulated as an intranasal drug-device combination product. DB503 has shown compelling pre-clinical disease efficacy in several mouse TBI models. The program integrates formulation and drug/device development, dose optimization in murine models, and translational pharmacology and efficacy evaluation in a porcine controlled cortical impact model.

UT Health San Antonio is dedicated to educating the next generation of health care professionals, conducting innovative research, and providing high-quality patient care. With a commitment to community service, the institution aims to improve health outcomes in South Texas and beyond through its six schools and numerous degree programs.

Indiana University is dedicated to building a better future through education, research, and community engagement. With a commitment to academic excellence, IU offers a diverse range of programs across its nine campuses, fostering an inclusive environment for over 90,000 students from around the world. IU is also at the forefront of groundbreaking research, particularly in areas such as brain health and Alzheimer's disease.

MyFitStrip is a precision wellness platform advancing oral and metabolic health by restoring nitric oxide (NO) bioavailability through clinically grounded, microbiome-directed interventions. Built on validated nitrate–nitrite–NO biology, MyFitStrip uses topical oral delivery (chewing gums and lozenges) to enhance nitric oxide production directly within the oral microbiome—supporting beneficial bacteria (e.g., Neisseria, Rothia, Veillonella) while suppressing pathogenic species linked to inflammation, caries, and infection risk. This approach targets a critical physiological pathway, with evidence linking nitric oxide to vascular function, immune defense, and metabolic health, including improvements in endothelial function, blood pressure regulation, antimicrobial activity, and oral pH balance. The platform is complemented by rapid saliva-based test strips that measure nitric oxide status, pH, and uric acid—creating a closed-loop system that drives personalization, compliance, and real-time lifestyle feedback. MyFitStrip’s product suite includes prebiotic chewing gums, slow-release lozenges, and diagnostic strips, all supported by a portfolio of nitric oxide–related patents and a deep body of clinical and scientific research spanning immunology, cardiovascular health, and microbiome science. MyFitStrip is defining a new category at the intersection of oral microbiome modulation and nitric oxide biology, enabling scalable, non-invasive solutions for oral-systemic health optimization.

Houston Methodist Academic Institute integrates advanced clinical research, education, and healthcare innovation with a focus on translating scientific discoveries into improved patient outcomes. The institute offers accredited graduate and postgraduate medical education, supports interdisciplinary research in major areas such as cancer, cardiology, neuroscience, transplant medicine, and regenerative medicine, and provides extensive infrastructure for digital health and medical technology development. Training and fellowship programs span from medical residencies and fellowships to doctoral and research-oriented positions, supported by collaborations with leading academic and industry partners. The institute leverages core technology platforms, simulation centers, and comprehensive educational pathways to foster future leaders in medicine and biomedical research.

Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.

UT Southwestern Medical Center is a premier academic medical institution dedicated to advancing medical science and improving health care through excellence in education, research, and patient care. The center is renowned for its collaborative environment that fosters innovation and discovery, housing distinguished faculty including Nobel Laureates. UT Southwestern is recognized for its groundbreaking research, comprehensive educational programs, and commitment to patient care, serving millions annually across its facilities.

Yale University, founded in 1701, is dedicated to expanding and sharing knowledge, inspiring innovation, and preserving cultural and scientific information for future generations. It engages with local and global communities to promote cultural understanding and improve the human condition.

The University of Tennessee, Knoxville is dedicated to advancing knowledge and understanding through research, scholarship, and creative work. The Office of Research, Innovation, and Economic Development supports faculty, staff, and students in developing competitive proposals and fostering a strong culture of research integrity, aiming to create a more just, prosperous, and sustainable world.

The Geneva Foundation is a 501(c)3 nonprofit established in 1993, dedicated to advancing military medicine through research, development, and education. With a commitment to ensuring optimal health for service members and the communities they serve, Geneva collaborates with various partners to drive innovative medical research and improve healthcare outcomes.

Tensentric is a contract design and manufacturing firm focused solely on medical device, in vitro diagnostic, and advanced therapy markets. We're ISO13485 certified and FDA registered to help our clients bring their new technology and products to market.

Signature Science, LLC is a multidisciplinary applied science and technology company dedicated to solving the toughest forensic, biosecurity, and public health challenges. Serving both government and commercial clients, Signature Science combines scientific rigor with proven quality assurance to enhance the credibility and defensibility of programs in national security, public safety, and health security. The company is recognized for its innovation, technical excellence, and commitment to advancing the state-of-the-art in forensic science, genomics, and biosecurity technologies. Signature Science also offers advanced bioinformatics and microbiome analysis services, empowering clients with data-driven insights to address emerging threats, pandemics, and bioterrorism. The company is a subsidiary of Southwest Research Institute and is committed to community engagement and workforce development.

Thendor Therapeutics is an early-stage biotechnology company focused on developing therapies aimed at reversing, halting, and preventing fibrosis across multiple organ systems. Leveraging peptide-based drug discovery, the company's mission is to restore tissue function and improve patient outcomes in pulmonary, urological, and systemic fibrotic diseases. Through a combination of targeted pathway research, regenerative approaches, and platform innovation, Thendor Therapeutics seeks to address unmet needs in fibrotic disease, which currently lacks effective treatments.

The Texas A&M Engineering Experiment Station (TEES) is a state agency and part of the Texas A&M University System, dedicated to improving lives through engineering research, workforce development, and technology transition. TEES collaborates with industry, academia, and government to provide innovative solutions to global technical challenges.